Reusing them introduces contamination risk into both the vial and the injection
BREAKING NEWS APRIL 15, 2026 - In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500
Intratubular albumin blunts the response to furosemide a mechanism for diuretic resistance in the nephrotic syndrome
These are designed for comfort and ease of use
Creating your own serum allows higher concentrations and customized ingredient combinations